Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 5, 2002, Pages 1336-1339

  Tremblay, Cécile L ^a   Giguel, Françoise ^a   Kollmann, Christopher ^a   Guan, Yongbiao ^a   Chou, Ting Chao ^a   Baroudy, Bahige M ^a   Hirsch, Martin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; AMINOOXYPENTANE RANTES; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CYCLIC N-OXIDES; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; PIPERIDINES; PYRIDINES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0036232981     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.5.1336-1339.2002     Document Type: Article

References (23)

1. Antiretroviral therapy for HIV infection in 2000: Updated recommendations of the International AIDS Society-USA panel
2. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes: A cohort study
3. HIV entry and its inhibition
4. The median-effect principle and the combination index for quantitation of synergism and antagonism
5. Change in coreceptor use correlates with disease progression in HIV-1infected individuals
6. HIV-1 membrane fusion: Targets of opportunity
7. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
8. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
9. In vivo antagonism with zidovudine plus stavudine combination therapy
10. Antiretroviral drug resistance testing in adults with HIV infection: Recommendations of an International AIDS Society-USA panel
11. Identification of the envelope V3 loop as the primary, determinant of cell tropism in HIV-1
12. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
13. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro
14. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro
15. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
16. Sequential versus simultaneous combination antiretroviral regimens for the treatment of human immunodeficiency virus type 1 infection in vitro
17. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
18. Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual
19. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
20. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
21. Combination antiretroviral therapy
22. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100
23. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens